Skip to main content
. 2022 Jul 4;20:98. doi: 10.1186/s12958-022-00961-y

Table 2.

Basic patient characteristics and results of hormonal testing in FHA women with and without PCOM

FHA without PCOM (n = 37) FHA with PCOM (n = 27) Controls (n = 32) p
Age (years) 26 (21;30) 26 (21;28) 26 (23;28) 0.731
BMI (kg/m2) 20.0 (18.5;21.6) 20.4 (18.6;23.2) 21.5 (19.6;23.6) 0.131
TSH (IU/mL) 1.78 (1.17;2.04) 1.49 (1.08;2.36) 1.41 (1.05;1.93) 0.400
FSH (mIU/mL) 4.0 (2.6;6.1) 4.6 (3.5;6.5) 5.7 (4.4;7.6) 0.034
LH (mIU/mL) 2.6 (1.2;4.9)b 2.6 (1.3;6.3)c 4.7 (3.4;7.0)b c 0.001
Prolactin (ng/mL) 7.9 (6.5;12.2)b 9.3 (6.6;13.1) 11.8 (9.0;15.4)b 0.013
Estradiol (pg/mL) 23 (16;35)b 30 (11;45)c 71 (50;97)b c  < 0.001
Testosterone (pg/mL) 0.22 (0.13;0.30) 0.22 (0.15;0.30) 0.25 (0.17;0.31) 0.695
Androstenedione (ng/mL) 1.29 (0.93;2.10) 1.65 (1.09;2.62) 1.54 (1.18;2.04) 0.269
DHEAS (µg/mL) 2.01 (1.47;3.25 2.33 (1.56;2.84) 2.18 (1.76;2.74) 0.926
SHBG (nmol/L) 79.4 (60.3;120.9) 68.3 (37.7;99.8) 81.2 (61.;104.5) 0.144
AMH (ng/mL) 2.03 (1.40;2.50)a b 6.38 (4.34;10.10)a c 3.08 (2.24;4.10)b c  < 0.001

Variables are expressed as median (IQR); non-parametric Anovas with post hoc Bonferonni correction were perfomed

asignificantly different between FHA without PCOM and FHA with PCOM

bsignificantly different between FHA without PCOM and controls

csignificantly different between FHA with PCOM and controls